ストックスクリーナーアプリを入手
2.725
4.39%
-0.125
前日終値:
$2.85
開ける：
$2.81
24時間の取引高:
599.04K
Relative Volume:
0.27
時価総額：
$367.86M
収益：
-
当期純損益:
$-35.47M
株価収益率:
-4.7807
EPS:
-0.57
ネットキャッシュフロー:
$-124.27M
1週間 パフォーマンス:
-10.36%
1か月 パフォーマンス:
-0.55%
6か月 パフォーマンス:
+245.29%
1年 パフォーマンス:
+74.68%
1日の値動き範囲:
$2.72
$2.82
1週間の範囲:
$2.71
$3.27
52週間の値動き範囲:
$0.4603
$7.13
Prokidney Corp Stock (PROK) Company Profile
PROK を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PROK
Prokidney Corp
|
2.725 | 387.54M | 0 | -35.47M | -124.27M | -0.57 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.13 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
631.77 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
425.79 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
838.72 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
184.38 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
Prokidney Corp Stock (PROK) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-30 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2024-09-30 | 開始されました | JP Morgan | Neutral |
| 2024-09-10 | 開始されました | Guggenheim | Buy |
| 2024-03-07 | 再開されました | Morgan Stanley | Equal-Weight |
| 2024-01-02 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-07-25 | 開始されました | BTIG Research | Buy |
| 2022-12-21 | 開始されました | Jefferies | Buy |
| 2022-11-10 | 開始されました | Morgan Stanley | Equal-Weight |
| 2022-10-18 | 開始されました | UBS | Buy |
| 2022-10-14 | 開始されました | Citigroup | Buy |
| 2022-09-23 | 開始されました | BofA Securities | Buy |
| 2022-09-02 | 開始されました | Evercore ISI | Outperform |
すべてを表示
Prokidney Corp (PROK) 最新ニュース
What candlestick patterns are forming on ProKidney Corp.July 2025 Analyst Calls & AI Powered Buy and Sell Recommendations - newser.com
Will ProKidney Corp. stock beat EPS estimatesEarnings Miss & Daily Entry Point Alerts - newser.com
What data driven models say about ProKidney Corp.’s future2025 Breakouts & Breakdowns & Free Reliable Trade Execution Plans - newser.com
Is now a turning point for ProKidney Corp.Quarterly Performance Summary & AI Powered Buy and Sell Recommendations - newser.com
Is ProKidney Corp. stock poised for growthWeekly Trade Summary & Daily Volume Surge Signals - newser.com
Automated trading signals detected on ProKidney Corp.Weekly Trend Recap & AI Driven Stock Movement Reports - newser.com
Heatmap analysis for ProKidney Corp. and competitorsJuly 2025 Fed Impact & Scalable Portfolio Growth Methods - newser.com
What valuation multiples suggest for ProKidney Corp. stockJuly 2025 EndofMonth & Reliable Price Breakout Alerts - newser.com
What to expect from ProKidney Corp. in the next 30 daysPortfolio Profit Report & Trade Opportunity Analysis - newser.com
Visual analytics tools that track ProKidney Corp. performancePortfolio Update Report & Weekly Setup with High ROI Potential - newser.com
Will ProKidney Corp. stock recover faster than peersShare Buyback & Verified Momentum Stock Watchlist - newser.com
Will ProKidney Corp. stock go up soonRisk Management & Long-Term Safe Investment Ideas - newser.com
How ProKidney Corp. stock performs in stagflationSwing Trade & Community Trade Idea Sharing - newser.com
What technical charts say about ProKidney Corp. stockJuly 2025 EndofMonth & Growth Oriented Trading Recommendations - newser.com
ProKidney (NASDAQ:PROK) Shares Down 8.2%Should You Sell? - MarketBeat
ProKidney to Participate in Two Upcoming Conferences: Guggenheim Healthcare Innovation Conference and the Jefferies Global Healthcare Conference - The Manila Times
Kymera Therapeutics to Report Third Quarter 2025 Financial Results on November 4, 2025 - Investing News Network
Prokidney Corp (PROK) 財務データ
収益
当期純利益
現金流量
EPS
1.14%
0.01%
大文字化:
|
ボリューム (24 時間):